ECCO Guidelines on Therapeutics in Crohn`s Disease: Medical Treatment - 2024

The European Crohn’s and Colitis Organisation (ECCO) reviewed the latest high-quality evidence on the medical management of Crohn’s disease and developed evidence-based recommendations for the treatment of adults. This 2024 edition builds on and expands the scope of the 2020 guidelines, ensuring clinicians have access to the most current guidance for optimal patient care.

What’s new?

• Updated evidence base: Incorporates the latest clinical trial data and real-world evidence published since 2020.
• Expanded therapeutic landscape: Includes new guidance on recently approved therapies, such as newer biologics and small molecules.
• Refined treatment algorithms: Adjustments to induction and maintenance strategies for different disease phenotypes and patient profiles.
• Emphasis on treat-to-target strategies: Reflects the evolution from symptom-based management to a target-driven approach, aiming for objective measures such as endoscopic healing and improved long-term outcomes.
• Greater focus on individualized care: Emphasizes shared decision-making, patient preferences, and risk stratification.
• Clarified positioning of therapies: Updated sequencing and combination strategies for biologics, immunomodulators, and small molecules.
• Integration of new research: Reflects advances in understanding of disease mechanisms, biomarkers, and personalized medicine.

Read the full article here:
https://academic.oup.com/ecco-jcc/article